ras peptide-specific activated autologous t lymphocytes

ras peptide-specific activated autologous t lymphocytes is an experimental adoptive cell therapy consisting of a patient's own T lymphocytes that have been sensitized and expanded ex vivo to target mutated Ras proteins. The process involves harvesting T cells from a patient, culturing them with synthetic peptides representing common oncogenic Ras mutations (such as KRAS G12D or G12V), and re-infusing the activated cells back into the patient. These sensitized T cells are designed to recognize and eliminate tumor cells that present these specific mutant Ras neoantigens via the major histocompatibility complex (MHC). Developed primarily by researchers at the National Cancer Institute (NCI), this therapy aims to exploit the high prevalence of Ras mutations in solid tumors, particularly in pancreatic, colorectal, and lung cancers, providing a personalized approach to targeting a key driver of malignancy.

Other names

ras peptide-sensitized autologous T lymphocytesmutant ras-specific activated autologous T-lymphocytesras peptide-specific T cellsmutated ras peptide-specific activated autologous T lymphocytes